These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 32567177)
21. Longitudinal assessment of cardiac parameters through MRI in breast cancer patients treated with anti-HER2 therapy. Cheng S; Wang J; Wang Y; Qi L; Li F; Liu J; Chen J; Fan Y; Xie L Eur Radiol Exp; 2023 May; 7(1):22. PubMed ID: 37183212 [TBL] [Abstract][Full Text] [Related]
22. Doxorubicin and trastuzumab regimen induces biventricular failure in mice. Milano G; Raucci A; Scopece A; Daniele R; Guerrini U; Sironi L; Cardinale D; Capogrossi MC; Pompilio G J Am Soc Echocardiogr; 2014 May; 27(5):568-79. PubMed ID: 24534652 [TBL] [Abstract][Full Text] [Related]
23. Early detection of myocardial changes with and without dexrazoxane using serial magnetic resonance imaging in a pre-clinical mouse model. Noel CV; Rainusso N; Robertson M; Romero J; Masand P; Coarfa C; Pautler R Cardiooncology; 2021 Jun; 7(1):23. PubMed ID: 34134789 [TBL] [Abstract][Full Text] [Related]
24. The Cardioprotective Role of Flaxseed in the Prevention of Doxorubicin- and Trastuzumab-Mediated Cardiotoxicity in C57BL/6 Mice. Asselin CY; Lam A; Cheung DYC; Eekhoudt CR; Zhu A; Mittal I; Mayba A; Solati Z; Edel A; Austria JA; Aukema HM; Ravandi A; Thliveris J; Singal PK; Pierce GN; Niraula S; Jassal DS J Nutr; 2020 Sep; 150(9):2353-2363. PubMed ID: 32510147 [TBL] [Abstract][Full Text] [Related]
25. Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors. Jordan JH; Vasu S; Morgan TM; D'Agostino RB; Meléndez GC; Hamilton CA; Arai AE; Liu S; Liu CY; Lima JA; Bluemke DA; Burke GL; Hundley WG Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27502058 [TBL] [Abstract][Full Text] [Related]
26. An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity. Cove-Smith L; Woodhouse N; Hargreaves A; Kirk J; Smith S; Price SA; Galvin M; Betts CJ; Brocklehurst S; Backen A; Radford J; Linton K; Roberts RA; Schmitt M; Dive C; Tugwood JD; Hockings PD; Mellor HR Toxicol Sci; 2014 Jul; 140(1):3-15. PubMed ID: 24675088 [TBL] [Abstract][Full Text] [Related]
27. Late characterisation of cardiac effects following anthracycline and trastuzumab treatment in breast cancer patients. Kimball A; Patil S; Koczwara B; Raman KS; Perry R; Grover S; Selvanayagam J Int J Cardiol; 2018 Jun; 261():159-161. PubMed ID: 29576422 [TBL] [Abstract][Full Text] [Related]
28. Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study. Gong IY; Ong G; Brezden-Masley C; Dhir V; Deva DP; Chan KKW; Graham JJ; Chow CM; Thavendiranathan P; Dai D; Ng MY; Barfett JJ; Connelly KA; Yan AT Int J Cardiovasc Imaging; 2019 Apr; 35(4):653-662. PubMed ID: 30390170 [TBL] [Abstract][Full Text] [Related]
29. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines. Barbosa MF; Fusco DR; Gaiolla RD; Werys K; Tanni SE; Fernandes RA; Ribeiro SM; Szarf G BMC Cardiovasc Disord; 2021 Apr; 21(1):170. PubMed ID: 33845778 [TBL] [Abstract][Full Text] [Related]
30. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer. Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235 [TBL] [Abstract][Full Text] [Related]